Information Provided By: 
Fly News Breaks for May 3, 2018
ABT, SRDX
May 3, 2018 | 08:46 EDT
Lake Street analyst Brooks O'Neil raised his price target for Surmodics (SRDX) to $76 after reconsidering the way he values the shares. The existing business is worth what the stock is trading for today, and SurVeil, the two other "high potential" products considered in the Abbott (ABT) agreement and the roughly 15 510 (K) products Surmodics is developing are worth about the same, O'Neil tells investors in a research note following the company's Q2 results. He keeps a Buy rating on the shares.
News For SRDX;ABT From the Last 2 Days
